{"schema_version":"secwatch.filing_event.v1","accession":"0001555280-26-000008","form_type":"8-K","ticker":"ZTS","cik":"0001555280","company_name":"Zoetis Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.417982+00:00","generated_at":"2026-05-16T03:01:05.300354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zoetis Q4 2025 revenue $2.4B (+3%), EPS $1.37; FY26 guidance $9.825-10.025B","bullets":["Q4 2025 revenue $2.4B (+3% reported, +4% organic); net income $603M (EPS $1.37, +6%).","Full year 2025 revenue $9.5B (+2% reported, +6% organic); adjusted EPS $6.41 (+8% reported).","FY 2026 guidance: revenue $9.825-10.025B (organic growth 3-5%); adjusted EPS $7.00-7.10.","U.S. segment revenue flat organically; International up 7% organic driven by parasiticide and livestock growth.","Acquired VPG in UK/Ireland; received approvals for long-acting OA pain mAbs Lenivia (dog) and Portela (cat) in Canada/EU."],"urls":{"canonical":"https://secwatch.observer/filing/0001555280-26-000008","json":"https://secwatch.observer/filing/0001555280-26-000008.json","markdown":"https://secwatch.observer/filing/0001555280-26-000008.md","text":"https://secwatch.observer/filing/0001555280-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555280/000155528026000008/0001555280-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555280/000155528026000008/zts-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:01:05.300354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}